@article{RN508,
   author = {Barchuk, A. and Barboza, C. and Politi, J. and Raventós, B. and Prinsen, P. and Evers, J. and Ho, V. K. and Van de Sande, M. A. and Fey, E. and Porkka, K. and Hammais, A. and Wahlfors, T. and Nieminen, T. and Lehtonen, T. and Delmestri, A. and Verdy, G. and Griffier, R. and De Burgos-González, A. and Llorente-Garcia, A. and Justo-Astorgano, C. and Macia-Martinez, M. A. and Tenhunen, O. and Schiel, A. and Pacurariu, A. and Brennan, R. and Williams, R. and Verhamme, K. and Duarte Salles, T.},
   title = {Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study},
   journal = {Acta Oncol},
   volume = {65},
   pages = {193-200},
   note = {1651-226x
Barchuk, Anton
Orcid: 0000-0002-4629-3326
Barboza, Cesar
Orcid: 0009-0002-4453-3071
Politi, Julieta
Orcid: 0000-0001-7315-034x
Raventós, Berta
Orcid: 0000-0002-4668-2970
Prinsen, Peter
Orcid: 0000-0002-0444-4579
Evers, Jelle
Orcid: 0000-0003-0525-9786
Ho, Vincent Ky
Orcid: 0000-0001-7065-928x
Van de Sande, Michiel Aj
Orcid: 0000-0002-9156-7656
Fey, Eric
Orcid: 0009-0005-7847-7479
Porkka, Kimmo
Orcid: 0000-0003-4112-5902
Hammais, Anna
Wahlfors, Tiina
Orcid: 0000-0002-3910-796x
Nieminen, Tuomo
Orcid: 0000-0002-6901-2208
Lehtonen, Toni
Orcid: 0000-0003-2089-2299
Delmestri, Antonella
Orcid: 0000-0003-0388-3403
Verdy, Guillaume
Orcid: 0000-0002-0745-0034
Griffier, Romain
Orcid: 0000-0002-1096-137x
De Burgos-González, Airam
Orcid: 0000-0002-4928-0491
Llorente-Garcia, Ana
Justo-Astorgano, Cristina
Macia-Martinez, Miguel-Angel
Orcid: 0000-0002-1471-4376
Tenhunen, Olli
Orcid: 0009-0009-0802-1619
Schiel, Anja
Orcid: 0000-0002-1258-4731
Pacurariu, Alexandra
Orcid: 0000-0002-2217-0540
Brennan, Ross
Williams, Ross
Orcid: 0000-0001-7723-417x
Verhamme, Katia
Orcid: 0000-0001-8162-4904
Duarte Salles, Talita
Orcid: 0000-0002-8274-0357
Journal Article
Sweden
2026/03/11
Acta Oncol. 2026 Mar 10;65:193-200. doi: 10.2340/1651-226X.2026.45117.},
   abstract = {BACKGROUND AND PURPOSE: Chondrosarcoma is a rare bone malignancy with a poor response to systemic therapy in advanced stages. European-level epidemiological data remain scarce. This study aimed to characterise patient demographics, treatments and survival using real-world data to inform regulatory decisions about the feasibility and design of new trials for the systemic treatment of chondrosarcoma. Patient/material and methods: This cohort study, part of the DARWIN EU® initiative, analysed data from six healthcare databases in Finland, France, the Netherlands, Spain and the UK. Patients diagnosed with chondrosarcoma between 2010 and 2022 were identified. Standardised analyses were performed within a federated network using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. RESULTS: A total of 2,498 chondrosarcoma patient records were identified, covering at least 2,356 unique patients. Median age at diagnosis was 52-55 years, with a balanced sex distribution. Surgical treatment was the most common intervention, recorded in 15.2% to 88.9% of patients, depending on the database. Fewer than 5% received systemic anticancer therapy, and radiotherapy was reported in fewer than 7%. The 10-year overall survival (OS) ranged from 58% (95% confidence interval [CI]: 43-78) to 80% (95% CI: 78-82), with restricted mean survival between 7.4 and 8.7 years. In the Netherlands, patients with late-stage, metastatic or high-grade disease showed significantly poorer outcomes. INTERPRETATION: This study demonstrates the feasibility of using real-world data across Europe to describe chondrosarcoma patients. Most had early-stage, low-grade disease amenable to surgery, with limited use of systemic therapies. Survival was generally favourable, except in advanced disease. Clinical trials remain difficult due to the rarity of advanced chondrosarcoma and the lack of standards.},
   keywords = {Humans
*Chondrosarcoma/therapy/mortality/pathology/epidemiology
Male
Female
*Bone Neoplasms/therapy/mortality/pathology/epidemiology
Middle Aged
Europe/epidemiology
Cohort Studies
Aged
Adult
Young Adult
Aged, 80 and over
Adolescent
Survival Rate},
   ISSN = {0284-186x},
   DOI = {10.2340/1651-226x.2026.45117},
   year = {2026},
   type = {Journal Article}
}

{"_id":"wufYFRPWspZjZwiim","bibbaseid":"barchuk-barboza-politi-ravents-prinsen-evers-ho-vandesande-etal-characteristicstreatmentandsurvivalofpatientswithchondrosarcomainfiveeuropeancountriesadarwineucohortstudy-2026","author_short":["Barchuk, A.","Barboza, C.","Politi, J.","Raventós, B.","Prinsen, P.","Evers, J.","Ho, V. K.","Van de Sande, M. A.","Fey, E.","Porkka, K.","Hammais, A.","Wahlfors, T.","Nieminen, T.","Lehtonen, T.","Delmestri, A.","Verdy, G.","Griffier, R.","De Burgos-González, A.","Llorente-Garcia, A.","Justo-Astorgano, C.","Macia-Martinez, M. A.","Tenhunen, O.","Schiel, A.","Pacurariu, A.","Brennan, R.","Williams, R.","Verhamme, K.","Duarte Salles, T."],"bibdata":{"bibtype":"article","type":"Journal Article","author":[{"propositions":[],"lastnames":["Barchuk"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Barboza"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Politi"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Raventós"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Prinsen"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Evers"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Ho"],"firstnames":["V.","K."],"suffixes":[]},{"propositions":["Van","de"],"lastnames":["Sande"],"firstnames":["M.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Fey"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Porkka"],"firstnames":["K."],"suffixes":[]},{"propositions":[],"lastnames":["Hammais"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Wahlfors"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Nieminen"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Lehtonen"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Delmestri"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Verdy"],"firstnames":["G."],"suffixes":[]},{"propositions":[],"lastnames":["Griffier"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["De","Burgos-González"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Llorente-Garcia"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Justo-Astorgano"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Macia-Martinez"],"firstnames":["M.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Tenhunen"],"firstnames":["O."],"suffixes":[]},{"propositions":[],"lastnames":["Schiel"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Pacurariu"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Brennan"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Williams"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Verhamme"],"firstnames":["K."],"suffixes":[]},{"propositions":[],"lastnames":["Duarte","Salles"],"firstnames":["T."],"suffixes":[]}],"title":"Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study","journal":"Acta Oncol","volume":"65","pages":"193-200","note":"1651-226x Barchuk, Anton Orcid: 0000-0002-4629-3326 Barboza, Cesar Orcid: 0009-0002-4453-3071 Politi, Julieta Orcid: 0000-0001-7315-034x Raventós, Berta Orcid: 0000-0002-4668-2970 Prinsen, Peter Orcid: 0000-0002-0444-4579 Evers, Jelle Orcid: 0000-0003-0525-9786 Ho, Vincent Ky Orcid: 0000-0001-7065-928x Van de Sande, Michiel Aj Orcid: 0000-0002-9156-7656 Fey, Eric Orcid: 0009-0005-7847-7479 Porkka, Kimmo Orcid: 0000-0003-4112-5902 Hammais, Anna Wahlfors, Tiina Orcid: 0000-0002-3910-796x Nieminen, Tuomo Orcid: 0000-0002-6901-2208 Lehtonen, Toni Orcid: 0000-0003-2089-2299 Delmestri, Antonella Orcid: 0000-0003-0388-3403 Verdy, Guillaume Orcid: 0000-0002-0745-0034 Griffier, Romain Orcid: 0000-0002-1096-137x De Burgos-González, Airam Orcid: 0000-0002-4928-0491 Llorente-Garcia, Ana Justo-Astorgano, Cristina Macia-Martinez, Miguel-Angel Orcid: 0000-0002-1471-4376 Tenhunen, Olli Orcid: 0009-0009-0802-1619 Schiel, Anja Orcid: 0000-0002-1258-4731 Pacurariu, Alexandra Orcid: 0000-0002-2217-0540 Brennan, Ross Williams, Ross Orcid: 0000-0001-7723-417x Verhamme, Katia Orcid: 0000-0001-8162-4904 Duarte Salles, Talita Orcid: 0000-0002-8274-0357 Journal Article Sweden 2026/03/11 Acta Oncol. 2026 Mar 10;65:193-200. doi: 10.2340/1651-226X.2026.45117.","abstract":"BACKGROUND AND PURPOSE: Chondrosarcoma is a rare bone malignancy with a poor response to systemic therapy in advanced stages. European-level epidemiological data remain scarce. This study aimed to characterise patient demographics, treatments and survival using real-world data to inform regulatory decisions about the feasibility and design of new trials for the systemic treatment of chondrosarcoma. Patient/material and methods: This cohort study, part of the DARWIN EU® initiative, analysed data from six healthcare databases in Finland, France, the Netherlands, Spain and the UK. Patients diagnosed with chondrosarcoma between 2010 and 2022 were identified. Standardised analyses were performed within a federated network using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. RESULTS: A total of 2,498 chondrosarcoma patient records were identified, covering at least 2,356 unique patients. Median age at diagnosis was 52-55 years, with a balanced sex distribution. Surgical treatment was the most common intervention, recorded in 15.2% to 88.9% of patients, depending on the database. Fewer than 5% received systemic anticancer therapy, and radiotherapy was reported in fewer than 7%. The 10-year overall survival (OS) ranged from 58% (95% confidence interval [CI]: 43-78) to 80% (95% CI: 78-82), with restricted mean survival between 7.4 and 8.7 years. In the Netherlands, patients with late-stage, metastatic or high-grade disease showed significantly poorer outcomes. INTERPRETATION: This study demonstrates the feasibility of using real-world data across Europe to describe chondrosarcoma patients. Most had early-stage, low-grade disease amenable to surgery, with limited use of systemic therapies. Survival was generally favourable, except in advanced disease. Clinical trials remain difficult due to the rarity of advanced chondrosarcoma and the lack of standards.","keywords":"Humans *Chondrosarcoma/therapy/mortality/pathology/epidemiology Male Female *Bone Neoplasms/therapy/mortality/pathology/epidemiology Middle Aged Europe/epidemiology Cohort Studies Aged Adult Young Adult Aged, 80 and over Adolescent Survival Rate","issn":"0284-186x","doi":"10.2340/1651-226x.2026.45117","year":"2026","bibtex":"@article{RN508,\r\n author = {Barchuk, A. and Barboza, C. and Politi, J. and Raventós, B. and Prinsen, P. and Evers, J. and Ho, V. K. and Van de Sande, M. A. and Fey, E. and Porkka, K. and Hammais, A. and Wahlfors, T. and Nieminen, T. and Lehtonen, T. and Delmestri, A. and Verdy, G. and Griffier, R. and De Burgos-González, A. and Llorente-Garcia, A. and Justo-Astorgano, C. and Macia-Martinez, M. A. and Tenhunen, O. and Schiel, A. and Pacurariu, A. and Brennan, R. and Williams, R. and Verhamme, K. and Duarte Salles, T.},\r\n title = {Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study},\r\n journal = {Acta Oncol},\r\n volume = {65},\r\n pages = {193-200},\r\n note = {1651-226x\r\nBarchuk, Anton\r\nOrcid: 0000-0002-4629-3326\r\nBarboza, Cesar\r\nOrcid: 0009-0002-4453-3071\r\nPoliti, Julieta\r\nOrcid: 0000-0001-7315-034x\r\nRaventós, Berta\r\nOrcid: 0000-0002-4668-2970\r\nPrinsen, Peter\r\nOrcid: 0000-0002-0444-4579\r\nEvers, Jelle\r\nOrcid: 0000-0003-0525-9786\r\nHo, Vincent Ky\r\nOrcid: 0000-0001-7065-928x\r\nVan de Sande, Michiel Aj\r\nOrcid: 0000-0002-9156-7656\r\nFey, Eric\r\nOrcid: 0009-0005-7847-7479\r\nPorkka, Kimmo\r\nOrcid: 0000-0003-4112-5902\r\nHammais, Anna\r\nWahlfors, Tiina\r\nOrcid: 0000-0002-3910-796x\r\nNieminen, Tuomo\r\nOrcid: 0000-0002-6901-2208\r\nLehtonen, Toni\r\nOrcid: 0000-0003-2089-2299\r\nDelmestri, Antonella\r\nOrcid: 0000-0003-0388-3403\r\nVerdy, Guillaume\r\nOrcid: 0000-0002-0745-0034\r\nGriffier, Romain\r\nOrcid: 0000-0002-1096-137x\r\nDe Burgos-González, Airam\r\nOrcid: 0000-0002-4928-0491\r\nLlorente-Garcia, Ana\r\nJusto-Astorgano, Cristina\r\nMacia-Martinez, Miguel-Angel\r\nOrcid: 0000-0002-1471-4376\r\nTenhunen, Olli\r\nOrcid: 0009-0009-0802-1619\r\nSchiel, Anja\r\nOrcid: 0000-0002-1258-4731\r\nPacurariu, Alexandra\r\nOrcid: 0000-0002-2217-0540\r\nBrennan, Ross\r\nWilliams, Ross\r\nOrcid: 0000-0001-7723-417x\r\nVerhamme, Katia\r\nOrcid: 0000-0001-8162-4904\r\nDuarte Salles, Talita\r\nOrcid: 0000-0002-8274-0357\r\nJournal Article\r\nSweden\r\n2026/03/11\r\nActa Oncol. 2026 Mar 10;65:193-200. doi: 10.2340/1651-226X.2026.45117.},\r\n abstract = {BACKGROUND AND PURPOSE: Chondrosarcoma is a rare bone malignancy with a poor response to systemic therapy in advanced stages. European-level epidemiological data remain scarce. This study aimed to characterise patient demographics, treatments and survival using real-world data to inform regulatory decisions about the feasibility and design of new trials for the systemic treatment of chondrosarcoma. Patient/material and methods: This cohort study, part of the DARWIN EU® initiative, analysed data from six healthcare databases in Finland, France, the Netherlands, Spain and the UK. Patients diagnosed with chondrosarcoma between 2010 and 2022 were identified. Standardised analyses were performed within a federated network using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. RESULTS: A total of 2,498 chondrosarcoma patient records were identified, covering at least 2,356 unique patients. Median age at diagnosis was 52-55 years, with a balanced sex distribution. Surgical treatment was the most common intervention, recorded in 15.2% to 88.9% of patients, depending on the database. Fewer than 5% received systemic anticancer therapy, and radiotherapy was reported in fewer than 7%. The 10-year overall survival (OS) ranged from 58% (95% confidence interval [CI]: 43-78) to 80% (95% CI: 78-82), with restricted mean survival between 7.4 and 8.7 years. In the Netherlands, patients with late-stage, metastatic or high-grade disease showed significantly poorer outcomes. INTERPRETATION: This study demonstrates the feasibility of using real-world data across Europe to describe chondrosarcoma patients. Most had early-stage, low-grade disease amenable to surgery, with limited use of systemic therapies. Survival was generally favourable, except in advanced disease. Clinical trials remain difficult due to the rarity of advanced chondrosarcoma and the lack of standards.},\r\n keywords = {Humans\r\n*Chondrosarcoma/therapy/mortality/pathology/epidemiology\r\nMale\r\nFemale\r\n*Bone Neoplasms/therapy/mortality/pathology/epidemiology\r\nMiddle Aged\r\nEurope/epidemiology\r\nCohort Studies\r\nAged\r\nAdult\r\nYoung Adult\r\nAged, 80 and over\r\nAdolescent\r\nSurvival Rate},\r\n ISSN = {0284-186x},\r\n DOI = {10.2340/1651-226x.2026.45117},\r\n year = {2026},\r\n type = {Journal Article}\r\n}\r\n\r\n","author_short":["Barchuk, A.","Barboza, C.","Politi, J.","Raventós, B.","Prinsen, P.","Evers, J.","Ho, V. K.","Van de Sande, M. A.","Fey, E.","Porkka, K.","Hammais, A.","Wahlfors, T.","Nieminen, T.","Lehtonen, T.","Delmestri, A.","Verdy, G.","Griffier, R.","De Burgos-González, A.","Llorente-Garcia, A.","Justo-Astorgano, C.","Macia-Martinez, M. A.","Tenhunen, O.","Schiel, A.","Pacurariu, A.","Brennan, R.","Williams, R.","Verhamme, K.","Duarte Salles, T."],"key":"RN508","id":"RN508","bibbaseid":"barchuk-barboza-politi-ravents-prinsen-evers-ho-vandesande-etal-characteristicstreatmentandsurvivalofpatientswithchondrosarcomainfiveeuropeancountriesadarwineucohortstudy-2026","role":"author","urls":{},"keyword":["Humans *Chondrosarcoma/therapy/mortality/pathology/epidemiology Male Female *Bone Neoplasms/therapy/mortality/pathology/epidemiology Middle Aged Europe/epidemiology Cohort Studies Aged Adult Young Adult Aged","80 and over Adolescent Survival Rate"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/network/files/qwipow2DJsAxqNp83","dataSources":["PcZMFHooKwpboi2he","jZMXEeHTfokmisJDv"],"keywords":["humans *chondrosarcoma/therapy/mortality/pathology/epidemiology male female *bone neoplasms/therapy/mortality/pathology/epidemiology middle aged europe/epidemiology cohort studies aged adult young adult aged","80 and over adolescent survival rate"],"search_terms":["characteristics","treatment","survival","patients","chondrosarcoma","five","european","countries","darwin","cohort","study","barchuk","barboza","politi","raventós","prinsen","evers","ho","van de sande","fey","porkka","hammais","wahlfors","nieminen","lehtonen","delmestri","verdy","griffier","de burgos-gonzález","llorente-garcia","justo-astorgano","macia-martinez","tenhunen","schiel","pacurariu","brennan","williams","verhamme","duarte salles"],"title":"Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study","year":2026}